REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1583363
This article is part of the Research TopicAdvances in Combined Modality Treatments for Prostate CancerView all articles
Prostate cancer immunotherapy-based strategies: An updated review emphasizing immune checkpoint inhibitors
Provisionally accepted
- Department of Urology, Qilu Hospital of Shandong University, Dezhou Hospital, Dezhou, 253032，China, Dezhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Prostate cancer (PC) is one of the most common cancers that is diagnosed in about 10-15% of men in old age. It seems that the current treatments are not effective, and this leads to prostate cancer becoming the second-deadliest cancer. Treatments such as chemotherapy, radiotherapy, androgen deprivation therapy (ADT), and surgery are among these treatments. However, the possibility of disease recurrence after these treatments is high. Therefore, other methods have become necessary, and PC treatment is changing. One of the methods that has received much attention today is immunotherapy. Immunotherapy includes all interventions that help to treat cancer or any other disease by affecting the immune system's responses. For this purpose, cytokines, cell therapy, and antibody-based methods can be used. Antibody-based treatments include immune checkpoint inhibitors (ICIs), and due to the high expression of immune checkpoint (ICP) molecules on the surface of prostate cancer cells and cancer stromal cells, these treatments have yielded promising results. Also, combining them with chemotherapy, surgery, and radiotherapy can help increase their efficiency. This review first updates standard treatments' therapeutic efficacy and risk factors. Then, we will talk about different types of immunotherapies, emphasizing ICIs.
Keywords: prostate cancer, Immunotherapy, immune checkpoint inhibitors, Treatment, combined therapy
Received: 25 Feb 2025; Accepted: 20 May 2025.
Copyright: © 2025 Lu, Teng, Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wenchao Zhang, Department of Urology, Qilu Hospital of Shandong University, Dezhou Hospital, Dezhou, 253032，China, Dezhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.